Biocare Medical's ONCORE Pro X™ Automated Slide Stainer: An Integral Part of DC3 Therapeutics’ Improved Diagnostic Workflow
November 6, 2023 – Biocare Medical, a trusted provider of immunohistochemistry (IHC) instrumentation, antibodies and molecular probes for tumor diagnostics, is proud to announce a strategic partnership with DC3 Therapeutics as their preferred vendor. DC3 Therapeutics is a world-class full-service Contract Research Organization (CRO) with extensive experience in drug development and the pharmaceutical industry. The integration of Biocare Medical’s ONCORE Pro XTM Fully Automated Slide Stainer combined with Biocare’s extensive menu of IHC antibodies, detection kits, and ancillary reagents into DC3’s workflow marks a significant improvement in the efficiency and flexibility of their IHC testing. The fully open format of the ONCORE Pro XTM also expands DC3’s capabilities with advanced staining technologies such as multiplex immunofluorescence, ISH, and FISH, enabling scaling of spatial biology projects for their Biotech and Pharmaceutical clients.
Biocare Medical’s ONCORE Pro XTM is a fully automated slide stainer designed to optimize staining processes by offering a broad menu, precision, control, consistency, flexibility, and reliability. Its successful integration into DC3’s workflow has been instrumental in bolstering their assay development capabilities and reducing turnaround time for IHC and multiplex immunofluorescence testing.
DC3 Therapeutics, a full-service Contract Research Organization (CRO), needed a platform to support the volume growth of IHC and to offer capability to develop spatial technologies within their histopathology laboratory. The partnership with Biocare Medical as their preferred vendor underscores the effectiveness of the ONCORE Pro XTM technology. The increased capabilities, consistency, and flexibility provided by the ONCORE Pro XTM has led to an improvement in DC3’s capability to provide spatial testing services that offer the value and quality of data Pharmaceutical and Biotech companies have come to expect. In addition to these technologies, DC3’s IHC testing capabilities are significantly enhanced by Biocare’s impressive antibody menu, which features over 325 markers and a collection of over 25 multiplex IHC markers, emphasizing the breadth and depth of their developmental and spatial testing menu.
About Biocare Medical
Biocare Medical is a global leader in solutions for cancer research and diagnostics, providing world-class reagents, including tissue-conserving simultaneous Multiplex IHC antibody cocktails and detections; renowned Customer Care; and a comprehensive suite of advanced instrumentation for IHC, molecular, and histology testing. Customers include clinical anatomic pathology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare’s reagent portfolio includes primary antibodies, Multiplex IHC, and FISH probes for target indications. Biocare also offers a unique line of polymer detections for clinical, human, and animal research that deliver high sensitivity and exceptionally low background. The Company’s advanced automated instrument platforms, intelliPATH™ and ONCORE Pro™ have been designed to meet every need from high throughput clinical diagnostics to flexible research requirements.
About DC3 Therapeutics
DC3 Therapeutics is a full-service preclinical, and COLA-accredited CLIA laboratory. Our team has extensive experience in the biotechnology and pharmaceutical industries, and we offer a full suite of services necessary for drug discovery and early development. Our commitment to customer service is a foundational pillar of our company, and we strive every day to deliver fast, accurate and reliable data to our clients.